Article Details
Retrieved on: 2018-04-16 17:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Firms like <b>Atlas Venture</b> have shown that de-risking biological investments early — in the seed stage — can have a huge impact. Atlas has achieved a 10% loss ratio (nearly 20% lower than the norm in biosciences) in part by encouraging truth-seeking behaviors and testing early on, even when it means ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here